| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-07-23 | Serum Institute of India (India) Vakzine Projekt Management GmbH (Germany) | VPM1002 | tuberculosis | licensing |
Infectious diseases | Licensing agreement |
| 2013-07-22 | Heptares Therapeutics (UK) Cubist Pharmaceuticals (USA - MA) | new medicines targeting G protein-coupled receptors (GPCRs) | undisclosed | R&D |
undisclosed | Milestone |
| 2013-07-19 | BiogenIdec (USA - MA) The University of Edinburgh (UK) | multiple sclerosis, motor neurone disease | R&D |
Autoimmune diseases – Neurodegenerative diseases - Neuromuscular diseases | R&D agreement | |
| 2013-07-17 | AstraZeneca (UK) Tufts University (USA) | R&D |
CNS diseases - Neurodegenerative diseases | R&D agreement | ||
| 2013-07-16 | Auxilium Pharmaceuticals (USA) Swedish Orphan Biovitrum (SOBI) (Sweden) | Xiapex®(EU)/ Xiaflex® (USA) (collagenase clostridium histolyticum) | Dupuytren's contracture, Peyronie's disease | development |
Development agreement | |
| 2013-07-16 | MDX Health (Belgium) - HistoGeneX (Belgium) | integrated molecular diagnostic testing services | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2013-07-16 | Valneva (France - Austria) Boehringer Ingelheim (Germany) | EB66® cell line | licensing |
Veterinary diseases | Licensing agreement | |
| 2013-07-16 | Argenta (Galapagos subsidiary – UK Belgium) Pcovery (Denmark) | medicinal chemistry and computer-aided drug design services | fungal infections | R&D |
Infectious diseases | R&D agreement |
| 2013-07-16 | Genzyme (USA - MA), a Sanofi company (France) Asklepios BioPharmaceutical (USA - NC) | Duplex gene therapy vector technology - Intra-Strand Base-Pairing technology | licensing |
Technology - Services | Licensing agreement | |
| 2013-07-16 | Merck KGaA, Merck Serono (Germany) Life Technologies (USA) | companion diagnostics projects | R&D |
Cancer - Oncology | R&D agreement | |
| 2013-07-15 | ARTES Biotechnology (Germany) Bio Farma (Indonesia) | vaccines | development |
Infectious diseases | Production agreement | |
| 2013-07-15 | Ipsen (France) Harvard Medical School (USA - MA) | novel engineered botulinum toxins | R&D |
Neurological diseases | R&D agreement | |
| 2013-07-15 | ADC Therapeutics (Switzerland) BZL Biologics (USA) | PSMA-specific antibody drug conjugate (ADC) | PSMA-positive prostate cancer | licensing |
Cancer - Oncology | Licensing agreement |
| 2013-07-15 | Marinomed Biotechnologie (Austria) undisclosed international pharmaceutical company | five medical products based on the MAVIREX® technology platform (antiviral nasal sprays against common cold, influenza and colds in children, antiviral lozenges and a throat spray against viral throat infections) | respiratory infections | licensing |
Infectious diseases - Respiratory diseases | Licensing agreement |
| 2013-07-15 | AstraZeneca (UK) Biosortia Pharmaceuticals (USA) | natural products derived from aquatic microbial consortia | R&D |
R&D agreement | ||
| 2013-07-12 | UCB (Belgium) Wilex (Germany) | undisclosed antibody program | Termination of an agreement | |||
| 2013-07-11 | Santhera Pharmaceuticals (Switzerland) European Vision Institute Clinical Research Network | Leber\'s Hereditary Optic Neuropathy (LHON) | collaboration |
Rare diseases - Genetic diseases - Ophtalmological diseases | Collaboration agreement | |
| 2013-07-09 | AstraZeneca (UK) the University of Cambridge (UK) Cancer Research UK (UK) the University of Manchester (UK) | three pre-clinical and clinical oncology projects related to olaparib, AZD2014 and new candidates | prostate cancer,pancreatic cancer, other cancers | R&D |
Cancer - Oncology | R&D agreement |
| 2013-07-09 | Blackfield (Germany) AstraZeneca (UK) | genomics technologies and computational biology capabilities to validate preclinical models | Cancer - Oncology | Services contract | ||
| 2013-07-09 | Vivus (USA - CA) Menarini (Italy) | Spedra™ (avanafil) | erectile dysfunction | commercialisation |
Commercialisation agreement |
